FDA approves Argenx's Vyvgart Hytrulo prefilled syringe for self-injection in gMG and CIDP, offering flexible dosing and expanding treatment options.

The global market for prefilled syringes is expanding, driven by the rising prevalence of chronic illnesses, greater use of biologics and biosimilars, and a growing trend toward self-injection.

Argenx’s VYVGART Hytrulo prefilled syringe for self-injection has received FDA approval for the treatment of adult patients ...

The global market for prefilled syringes is expanding, driven by the rising prevalence of chronic illnesses, greater use of biologics and biosimilars, and a growing trend toward self-injection.

The U.S. Food and Drug Administration has approved a prefilled syringe version of Netherlands-based Argenx SE's blockbuster ...

Already thriving with a successful launch of infused Vyvgart and its subcutaneous follow-on Vyvgart Hytrulo to the tune of $2 ...

“We understand patients experience MG and CIDP in different ways, and our prefilled syringe is an important innovation that provides patients with more freedom and flexibility to self-administer ...

After proper training on subcutaneous injection technique, the prefilled syringe may be administered by the patient or caregiver.

Argenx (ARGX) stock rises as the FDA approves Vyvgart Hytrulo developed with Halozyme (HALO) for self-injection, the drug's ...

(RTTNews) - Halozyme Therapeutics Inc. (HALO) announced that argenx has received U.S. Food and Drug Administration approval of VYVGART Hytrulo prefilled syringe for self-injection (efgartigimod ...